Cathie Wood's ARK ETF focuses on CRSP, BEAM stock buys

Cathie Wood's ARK ETFs made substantial portfolio adjustments on September 17, 2025, significantly increasing stakes in genomic and biotech firms, notably acquiring 339,924 shares of CRISPR Therapeutics for $20.8 million and 491,127 shares of Beam Therapeutics for $11.2 million. This strategic rebalancing also involved reducing holdings in Kratos Defense and Security Solutions by over $10 million, alongside sales in Roku and Tempus AI, underscoring ARK's ongoing commitment to high-growth companies, particularly within the genomics and technology sectors.

Analysis

Against the macroeconomic backdrop of a 0.25% Federal Reserve rate cut aimed at addressing a softening labor market, ARK Invest's daily trades on September 17, 2025, reveal a significant strategic concentration into high-growth biotechnology. The firm's flagship ARKK ETF executed substantial purchases, acquiring $20.8 million of CRISPR Therapeutics (CRSP) and $11.2 million of Beam Therapeutics (BEAM), reinforcing a pattern of consistent accumulation in these gene-editing leaders. This biotech focus was further underscored by a $2.6 million investment in Intellia Therapeutics (NTLA) and a $1.85 million purchase of Atai Life Sciences (ATAI). In a contrasting move, ARK demonstrated a clear divestment from Kratos Defense and Security Solutions (KTOS), selling over $10 million worth of shares across its ARKQ and ARKX ETFs. This notable sale, alongside smaller disposals of Roku (ROKU) and Tempus AI (TEM), suggests a deliberate portfolio rotation. The activity was not a broad exit from defense or tech, as ARK also tactically acquired positions in AeroVironment (AVAV) and L3Harris (LHX), indicating a nuanced preference for specific assets within these sectors.

Key Decisions for Investors

• Investors should note the strong institutional conviction signaled by ARK's significant and continued accumulation in the gene-editing sector, particularly through its $20.8 million purchase of CRISPR Therapeutics (CRSP) and $11.2 million purchase of Beam Therapeutics (BEAM).
• It is prudent to re-evaluate exposure to Kratos Defense (KTOS), as the substantial $10 million divestment by a key institutional manager may indicate a negative shift in its investment thesis or significant profit-taking.
• Recognize that ARK's activity reflects a tactical rotation rather than a simple sector bet, evidenced by its simultaneous selling of KTOS while purchasing other defense-related stocks like AeroVironment (AVAV) and L3Harris (LHX).